70315-70-7

Basic information

• Product Name: 3-Iodo-6-nitroindazole
• Synonyms: 3-IODO-6-NITRO (1H)INDAZOLE;3-IODO-6-NITROINDAZOLE;3-Iodo-6-nitro-1H-indazole ,97%;1H-Indazole, 3-iodo-6-nitro-;3-iodo-6-nitro-2h-indazole;Axitinib Intermediate;Axitinib Intermediate 1
• CAS NO: 70315-70-7
• Molecular Formula: C₇H₄IN₃O₂
• Molecular Weight: 289.03
• Product Categories: Indazoles;Intermediate of Axitinib
• Mol File: 70315-70-7.mol
• Article Data: 18

Chemical Properties

• Melting Point: 259-261 °C
• Boiling Point: 458.027 °C at 760 mmHg
• Flash Point: 230.807 °C
• Appearance: /
• Density: 2.24
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.818
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 9.12±0.40(Predicted)
• CAS DataBase Reference: 3-Iodo-6-nitroindazole(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Iodo-6-nitroindazole(70315-70-7)
• EPA Substance Registry System: 3-Iodo-6-nitroindazole(70315-70-7)

Safety Data

• Hazard Codes: Xn
• Statements: 22-60
• Safety Statements: 53-22-36/37/39-45
• WGK Germany: 3
• Hazardous Substances Data: 70315-70-7(Hazardous Substances Data)

Usage

Chemical Properties

Yellow solid

InChI:InChI=1/C7H4IN3O2/c8-7-5-2-1-4(11(12)13)3-6(5)9-10-7/h1-3H,(H,9,10)

Upstream product

• 99-55-8 2-methyl-5-nitroaniline 
• 7597-18-4 6-nitroindazole 

Downstream Products

• 858661-74-2 3-cyano-6-nitroindazole 
• 7597-18-4 6-nitroindazole 
• 1167056-71-4 methyl 6-nitro-1H-indazole-3-carboxylate 
• 885519-20-0 3-iodo-6-aminoindazole 
• 319460-85-0 axitinib 
• 885126-35-2 (E)-N-methyl-2-{[3-(2-(pyridin-2-yl)ethenyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-6-yl]thio}benzamide 
• 1204771-03-8 Ethyl 2-(6-amino-3-phenyl-1H-indazol-1-yl)thiazole-4-carboxylate 
• 1204772-52-0 C₁₈H₁₄N₄O₂S 
• 1204771-90-3 C₁₇H₁₂N₄O₂S 
• 1204773-04-5 ethyl 2-(6-nitro-3-phenyl-1H-indazol-1-yl)thiazole-4-carboxylate 
• 1204772-11-1 ethyl 2-{6-(methylamino)-3-phenyl-1H-indazol-1-yl}thiazole-4-carboxylate 
• 1133966-21-8 (E)-methyl 7-oxo-7-(2-(3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-ylthio)phenylamino)heptanoate 
• 1133966-20-7 (E)-2-(3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-ylthio)benzenamine 
• 1133966-19-4 (E)-ethyl 6-oxo-6-(2-(3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-ylthio)phenylamino)hexanoate 

Relevant articles and documents

NOVEL COMPOUNDS AND METHODS OF USE TREATING FRUCTOSE-RELATED DISORDERS OR DISEASES

Disclosed herein are novel compounds that inhibit fructokinase (KHK or ketohexokinase) and the downstream metabolic effects mediated by fructose metabolism. Fructokinase inhibitors specifically block the metabolism of both dietary and endogenous fructose

5-SULFAMOYL-2-HYDROXYBENZAMIDE DERIVATIVES

The invention is directed to substituted salicylamide derivatives. Specifically, the invention is directed to compounds according to Formula (I): wherein R, R1 and R2 are as defined herein, or a pharmaceutically acceptable salt thereof. The compounds of the invention are inhibitors of CD73 and can be useful in the treatment of cancer, pre-cancerous syndromes and diseases associated with CD73 inhibition, such as AIDS, the treatment of HIV, autoimmune diseases, infections, atherosclerosis, and ischemia–reperfusion injury. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting CD73 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

2,3-dimethyl-6-urea -2H-indazoles and its preparation method and application

The invention discloses a 2, 3-dimethyl-6-urea-2H-indazole compound shown by the following general formula (I), medicinal salt or a solvent compound thereof, wherein Ar is substituted or unsubstituted phenyl or aromatic matrix. The invention also discloses a preparation method and application of the compound. The compound can regulate signal transduction of tyrosine kinase, inhibit bad cellular proliferation, and particularly has obvious curative effect for tumors.